Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$8.33 USD
-0.15 (-1.77%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $8.34 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FOLD 8.33 -0.15(-1.77%)
Will FOLD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
Other News for FOLD
Interesting FOLD Put And Call Options For November 21st
Pocket Pivot appears for FOLD after 6.4% move
Amicus Therapeutics (FOLD) Upgraded by Needham with Increasing Sales Potential
Amicus upgraded to Buy at Needham banking on kidney disease therapy
Target initiated, Nike upgraded: Wall Street’s top analyst calls